
RBC Capital raised the firm’s price target on Diaceutics (DIUXF) to 240 GBp from 185 GBp and keeps an Outperform rating on the shares. Published first on TheFly – the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| DIUXF | Diaceutics | 2.31 | 1.10 | 90.56% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.31 | +90.56% |

RBC Capital raised the firm’s price target on Diaceutics (DIUXF) to 240 GBp from 185 GBp and keeps an Outperform rating on the shares. Published first on TheFly – the

The latest announcement is out from Diaceutics ( ($GB:DXRX) ). Diaceutics PLC, the AIM-listed diagnostics commercialization specialist serving leading pharma and biotech clients, is intensifying its investor outreach around precision

The latest announcement is out from Diaceutics ( ($GB:DXRX) ). Diaceutics PLC has provided an update on its UK and global employee share schemes, confirming that 316,969 ordinary shares were

The latest announcement is out from Diaceutics ( ($GB:DXRX) ). Diaceutics PLC has reported that trustees of its Global Diaceutics 2020 Employee Benefit Trust purchased ordinary shares on behalf of

An announcement from Diaceutics ( ($GB:DXRX) ) is now available. Diaceutics has expanded its multi-year Relay partnership with Syndax Pharmaceuticals to support the commercialization of a diagnostic-driven precision oncology therapy

The latest announcement is out from Diaceutics ( ($GB:DXRX) ). Diaceutics reported strong interim results for the six months to 30 June 2026, with annual recurring revenue jumping 79% to

Diaceutics ( ($GB:DXRX) ) has shared an update. Diaceutics PLC, the diagnostics intelligence and engagement specialist focused on improving access to precision therapies, plans to release its unaudited half-year results

An update from Diaceutics ( ($GB:DXRX) ) is now available. Diaceutics PLC has reported ongoing share purchases by three senior executives under its UK and Global Share Incentive Plans, with

Diaceutics ( ($GB:DXRX) ) has shared an announcement. Diaceutics PLC and the Precision Cancer Consortium have launched an NGS Concordance Study to evaluate how consistently genomic variants are detected across

Diaceutics ( ($GB:DXRX) ) just unveiled an update. Diaceutics PLC has expanded its employee share ownership framework, with trustees of its 2020 Employee Benefit Trust purchasing ordinary shares on behalf
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 13, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 15, 2027TBA | $220.90M | $0.06 | $37.99M | -11.04 | -617.19 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.